Biblio
Journal Article
von Tresckow J, Heyl N, Robrecht S, Giza A, Aldaoud A, Schlag R, Klausmann M, Linde H, Stein W, Schwarzer A, et al. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group. Ann Hematol. 2023.
von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink A-M, Al-Sawaf O, Fürstenau M, Illmer T, Klaproth H, Tausch E, et al. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia. 2022.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AMaria, Fürstenau M, Kater A, van der Spek E, et al. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. Am J Hematol. 2024.
Cramer P, von Tresckow J, Fink A-M, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Am J Hematol. 2024.